Ex­clu­sive: Theri­ni rais­es $36M, will tar­get fib­rin pro­tein for Alzheimer's and di­a­bet­ic mac­u­lar ede­ma

Theri­ni Bio has raised a $36 mil­lion Se­ries A and will head to the clin­ic with an an­ti­body that neu­tral­izes fib­rin, a blood clot­ting pro­tein, that it hopes could have broad ap­pli­ca­tions in tamp­ing down in­flam­ma­tion.

The fund­ing round, which in­clud­ed in­vest­ments from Eli Lil­ly, Sanofi and Mer­ck, will let Theri­ni move to­ward tests in Alzheimer’s dis­ease and di­a­bet­ic mac­u­lar ede­ma, the com­pa­ny told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER